Abstract: An NMR-based approachm arries the two traditional screening technologies (phenotypic and target-based screening) to find compounds inhibiting as pecific enzymatic reaction in bacterial cells.B uilding on ap revious study in which it was demonstrated that hydrolytic decomposition of meropenem in living Escherichia coli cells carrying New Delhi metallo-b-lactamase subclass 1(NDM-1) can be monitored in real time by NMR spectroscopy, we designed acell-based NMR screening platform. As trong NDM-1 inhibitor was identified with cellular IC 50 of 0.51 mm,w hich is over 300-fold more potent than captopril, ak nownN DM-1 inhibitor.T his new screening approach has great potential to be applied to targets in other cell types,such as mammalian cells,and to targets that are only stable or functionally competent in the cellular environment.
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Drug discovery often begins with screening ac ollection of compounds in the hope that some active molecules can be identified and later developed into drugs. [1] Phenotypic screens,w hich seek compounds that induce ac hange of phenotype in cells,tissues or organisms,were the mainstay of the drug discovery process before the genomics age. [2] Advances in molecular biology,g enomics,s tructural biology, and computational modeling subsequently shifted the search for drugs in favor of target-based approaches. [3] Both screening methods have their own advantages and disadvantages. [1, 4] Forp henotypic screens,amajor hurdle is understanding the mechanism of action behind screening hits,b ecause identification of the target(s) is critical for further optimization of compounds showing phenotypic interference.T arget-based screening,h owever,e mploys highly simplified systems in which targets are isolated from their complex biological networks.C lassical in vitro biochemistry and biophysics approaches are powerful methods for hit identification and verification, and structural biology plays akey role in guiding chemists to design specific and potent inhibitors.N evertheless,eventually those compounds showing activities in in vitro assays must prove to possess activity in vivo as well. Very often inhibitors fail at this stage owing to unfavorable physicochemical properties,efflux, and poor cell penetration. Thec oncept of "target-based" whole cell screening has been introduced recently to overcome some of these limitations whilst retaining the merits of both of these screening procedures.A pproaches exploiting antisense silencing technology or arrays of genetically-altered bacterial strains with inducible control of target expression have been used to screen for and identify inhibitors with antibacterial activity against pathogenic organisms.
[ [5] [6] [7] However,these approaches may still be susceptible to off-target-mediated effects,g iving rise to false positives.Hence,there is aneed for new screening methods that combine the rigor of in vitro target-based approaches with the biological context implicit in phenotypic screens.
Recently,w er eported that the hydrolysis of meropenem by E. coli cells carrying New Delhi metallo-b-lactamase subclass 1( NDM-1) can be readily monitored by 1 Hn uclear magnetic resonance spectroscopy (NMR). [8] This finding has led us to design an NMR-based whole cell screening experiment that utilizes 1 HNMR signals from meropenem (the substrate) and hydrolyzed meropenem (the product) as end points to detect enzyme inhibition in the native bacterial cell context ( Figure 1 ).
Bacteria produce av ariety of b-lactamases that defend them from attack by b-lactam antibiotics. [9] NDM-1 is aC lass Bo rm etallo-b-lactamase. [9, 10] In contrast to Class A, C, and D b-lactamases that exploit an active site serine residue to catalyze ring opening of b-lactams,C lass B blactamases utilize bound Zn 2+ ions to mediate hydrolysis.The recently discovered NDM-1 strains pose ap otential worldwide epidemic threat as bacteria carrying this enzyme may be rapidly disseminated across continents and become resistant to the majority of antibiotics including carbapenems,c onsidered one of the last lines of defense against serious bacterial infection. [11] Despite the urgent medical need, little advance has been made in the development of clinically useful NDM-1 inhibitors.
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To implement a9 6-well plate format to screen NDM1inhibitors,weselected 92 compounds that are either known metallo-b-lactamase inhibitors or derivatives of them.
[10] The first and last two wells act as controls and are filled with deuterated dimethyl sulfoxide ([D 6 ]DMSO) and ethylenediaminetetraacetic acid (EDTA). All compounds are dissolved in [D 6 ]DMSO to give af inal stock concentration of 100 mm. Thes creening experiment comprises three simple steps ( Figure 2 ): 1) compound incubation with NDM-1 E. coli cells;2 )addition of meropenem;a nd 3) NDM1-catalyzed hydrolysis reaction, quenched by addition of 10 mm EDTA. Thef inal concentrations for NMR detection are 500 mm compound, 100 mm meropenem, 0.5 %[ D 6 ]DMSO,a nd 10 mm EDTA. Under the conditions prior to the addition of 10 mm EDTA, the cells appear to be healthy (Supporting Information, Figure S2 ). Thee xperimental procedure of screening setup is detailed in the Supporting Information. After quenching the reaction, the plate was transferred to an automated NMR screening system to acquire 1D 1 HNMR spectra of each well on the plate. Figure 3p resents the 0.85-0.95 ppm region of 1 HNMR spectra from each well in a9 6-well plate format. For compounds with signals overlapping with the 0.9 ppm signal (for example,w ell A10 and G10 signals in Figure 3 ), methyl 1 Hs ignals around 1.1 and 2.9 ppm area can be examined for further validation (Supporting Information, Figure S1 ). In Figure 3 , signals of well A1 and H12 were blank controls in which only [D 6 ]DMSO was added. Examination of signals at 1.1 ppm indicates that meropenem was completely hydrolyzed. Signals of well A2 and H11 were from samples with 500 mm EDTA. Since EDTAisapotent inhibitor of NDM-1 in E. coli cells (the fifty percent inhibitory concentration, IC 50 ,is 1.6 mm), [8] hardly any product signal is detectable.T hus,these two wells represent positive controls for strong NDM1i nhibitors.
Thep otencyo fs creening hits was ranked as strong (> 80 %), medium (50-80 %), and weak (20-50 %) based on the percentage inhibition (Supporting Information, Table S1 ). As most compounds in the 96-well plate are either known Class B b-lactamase inhibitors or their derivatives,i ti sn ot surprising that ah igh hit rate of 34 %w as observed. Many compounds showed potencies similar to EDTA. We then determined by NMR spectroscopy the IC 50 values against NDM-1 enzymatic activity in bacterial cells of three screening hits (C10, A5, and B6) that were ranked as weak, medium, and strong, following our previously reported procedure (Figure 4) . [8] Thestrong and weak inhibitors from our NMRbased screen yielded IC 50 values of 0.51 and 120 mm,similar to those of EDTAa nd l-captopril (IC 50 = 175 mm), respectively. [8] Although only three compounds are shown here,a n initial structure-activity relationship emerges from the analysis of the chemical structures.A ll three compounds possess as imilar captopril-like scaffold. Evidently,t he carboxylate group on the right hand side of compound B6 and bulky aromatic groups play important roles in potency. An X-ray crystallography study of NDM-1/B6 complex structure is currently ongoing to investigate the key interactions contributing to the potency.
Using the same setup,weevaluated 92 hits from aconventional high-throughput phenotypic antibacterial screen of one million compounds run against the NDM-1 E. coli cells. Surprisingly,o nly 18 %o ft he hits from this screen were confirmed to inhibit meropenem hydrolysis in our whole-cell Stepwise preparation of at arget-based whole-cell screening plate for NMR data acquisition. Figure 3 . NMR screening results shown in a9 6-well plate format. The product signal at 0.9 ppm was used to monitor the inhibition. Weak, medium, and strong inhibitions are framed in red, blue and green boxes, respectively.
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Chemie NMR assay (data not shown). This illustrates clearly the ability of the whole cell-based NMR assay to directly detect hits by the desired mechanism of action, without the onerous requirement for additional assays to eliminate false positive hits,and further underlines the potential for our method to be integrated into drug discovery programs.
Although NMR spectroscopy is commonly applied in vitro to screen compound (and especially fragment) libraries against certain targets, [12] to the best of our knowledge NMR spectroscopy has not been applied to date for the screening of endogenous enzymes in whole cell samples.T he setup is straightforward and robust as long as as pecific enzymatic reaction or target binding is monitored and the solubility of the probed substrate is over 50 mm.I nc ontrast to other biophysical methods such as surface plasmon resonance and mass spectrometry,n oi mmobilization of cells or post-screen cell lysis are required. It is cost-effective and time-efficient as protein over-expression and purification steps are avoided. It takes approximately 5min to record data for one sample.I f am ixture of 5c ompounds were screened instead of the singlets as shown here,t he throughput would potentially be over 10 000 compounds per week. Furthermore,b ased on coarse ranking of compound potency, hits can be followed up by cellular IC 50 measurement using NMR spectroscopy,which can also be handled in an automated fashion. In summary,w eh ave developed an ovel NMR screening method for discovering inhibitors against as pecific target in cells where ad iffusible substrate or product can be monitored. This approach enjoys the merits of both target-based and whole-cell screening approaches.T he outcome of the screen is more predictive of ab iologically relevant effect because targets reside in the physiological environment in which enzymatic reactions and inhibition occur. [8] Thel aborious steps of target identification in traditional whole-cell screening are rendered unnecessary,a nd the gap in potency between in vitro and in vivo assays is bridged as compound permeability,e fflux pumps,a nd target accessibility are intrinsically factored in. This method can be applied to challenging proteins (for example,m embrane proteins) that are hard to obtain in purified, active form for in vitro assays. We believe that in principle this type of NMR screen has the potential to be adapted for use against other types of biological samples such as cancer cells,b lood cells,a nd viral particles.
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